gewrichtsaandoeningen chronic inflammatory joint disease rheumatic disorder Rheumatoid arthritis
Conditions
Interventions
Tocilizumab will be tapered every 3 months according to an existing dose
optimization protocol for tocilizumab. Tocilizumab trough levels will be
measured before every next dose tapering step.
If d
Sponsors
Franciscus Gasthuis & Vlietland
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - >=18 years of age - Diagnosed with rheumatoid arthritis and treated for it in Franciscus Gasthuis and Vlietland - Treated with intravenous or subcutaneous tocilizumab - Low disease activity for at least the last 6 months while using tocilizumab with a current DAS28-ESR
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoints of this study are: - the percentage of patients in whom tocilizumab is successfully tapered after 12 months (successful = lower dose than at baseline with a concurrent DAS28-ESR | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints of this study are: - the mean or median dose reduction or interval extension of tocilizumab between baseline and 12 months (in mg and percentages). - the mean or median change in disease activity scores between baseline and 12 months. | — |
Countries
Netherlands
Outcome results
None listed